SCHEMBL5498744

SCHEMBL5498744

FC(F)(F)COc1ccc(-c2nc(-c3cccnc3Cl)no2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.49
NPC1 O15118 7/20 0.49
SMN1; SMN2 Q16637 7/20 0.49
TP53 P04637 4/20 0.49
GAA P10253 1/20 0.49
MAPK1 P28482 1/20 0.49
STAT3 P40763 6/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2C9 P11712 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
NR1H4 Q96RI1 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
HSP90AA1 P07900 1/20 0.43
PKM P14618 1/20 0.43
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5494614 0.84 RAB9A (0.48) RAB9ANPC1SMN1; SMN2TP53GAA
SCHEMBL5494597 0.77 SMN1; SMN2 (0.61) RAB9ANPC1SMN1; SMN2TP53GAA
SCHEMBL19968904 0.76 STAT3 (0.54) RAB9ANPC1SMN1; SMN2STAT3CYP2C19
SCHEMBL5501327 0.73 S1PR1 (0.63) RAB9ANPC1SMN1; SMN2TP53GAA
SCHEMBL5959939 0.68 GRM5 (0.75) RAB9ANPC1SMN1; SMN2TP53MAPK1
SCHEMBL28134396 0.68 CYP1A2 (0.59) SMN1; SMN2CYP2C19CYP2C9MEN1CYP1A2
SCHEMBL3749726 0.67 NR1H4 (0.50) RAB9ANPC1SMN1; SMN2TP53NFKB1
SCHEMBL4186484 0.66 GRM5 (0.70) RAB9ANPC1SMN1; SMN2TP53MAPT
SCHEMBL1014151 0.66 HDAC1 (0.43) RAB9ANPC1SMN1; SMN2TP53MAPK1
SCHEMBL16481889 0.66 L3MBTL1 (0.47) RAB9ANPC1SMN1; SMN2GAACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1625123-A4 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS MERCK & CO INC (US) 2007-08-29 EP disclosed
US-20060252741-A1 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists MERCK & CO., INC. 2006-11-09 US disclosed
EP-1625123-A2 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS Merck & Co., Inc. (US) 2006-02-15 EP disclosed
WO-2004103279-A2 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS MERCK & CO., INC. (US) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252741-A1 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists S1PR1, S1PR3, S1PR5 RAB9A 2918/4885NPC1 963/4885SMN1; SMN2 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.